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Abstract
Ageing-associated changes that affect articular tissues promote the development of osteoarthritis 
(OA). Although ageing and OA are closely linked, they are independent processes. Several 
potential mechanisms by which ageing contributes to OA have been elucidated. This Review 
focuses on the contributions of the following factors: age-related inflammation (also referred to as 
‘inflammaging’); cellular senescence (including the senescence-associated secretory phenotype 
(SASP)); mitochondrial dysfunction and oxidative stress; dysfunction in energy metabolism due to 
reduced activity of 5′-AMP-activated protein kinase (AMPK), which is associated with reduced 
autophagy; and alterations in cell signalling due to age-related changes in the extracellular matrix. 
These various processes contribute to the development of OA by promoting a proinflammatory, 
catabolic state accompanied by increased susceptibility to cell death that together lead to increased 
joint tissue destruction and defective repair of damaged matrix. The majority of studies to date 
have focused on articular cartilage, and it will be important to determine whether similar 
mechanisms occur in other joint tissues. Improved understanding of ageing-related mechanisms 
that promote OA could lead to the discovery of new targets for therapies that aim to slow or stop 
the progression of this chronic and disabling condition.
A number of risk factors for the development of osteoarthritis (OA) exist, including prior 
joint injury, obesity, genetics, sex, and anatomical factors related to joint shape and 
alignment; however, the most prominent risk factor is increasing age1. A Spanish study 
published in 2014, which included more than 3 million individuals, examined the incidence 
of clinically diagnosed OA and reported that incident hand OA in women peaked between 
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the ages of 60 and 64 years, whereas that of the hip and knee continued to increase with 
increasing age2. A US study using data from the National Health Interview Survey reported 
that incident symptomatic knee OA peaked between the ages of 55 and 64, whereas 
prevalent disease increased with age, such that at age 85 years and older, prevalence ranged 
from ~13% in nonobese men to 32% in obese women3.
Musculoskeletal conditions, including OA, are a major cause of disability worldwide4 and 
have a substantial contribution to health-care costs, accounting for an estimated 1.0–2.5% of 
the gross domestic product in the USA, Canada, the UK, France and Australia5. Advanced 
OA often requires joint replacement to reduce pain and disability, and the number of knee 
replacement surgeries has substantially increased over the past 20 years6. The ageing of our 
population will compound the number of older adults disabled by OA and in need of joint 
replacement. Improved understanding of how ageing contributes to the development of OA 
could lead to new therapies that slow or stop the progression of the disease, which would 
have a major impact on public health.
OA that occurs in young adults is most often caused by a prior joint injury, a process known 
as post-traumatic OA1, whereas in older adults a number of factors related to ageing can 
contribute to the development of OA (BOX 1). These ‘ageing factors’ probably work in 
concert with other OA risk factors. Important differences between joint ageing and OA 
demonstrate that they are distinct processes (BOX 2). Although OA is a condition that 
affects the entire joint7 and results in joint failure, the majority of research to date has 
focused on ageing-associated changes in the articular cartilage. However, studies on the 
meniscus8, anterior cruciate ligament9 and bone10 have shown age-related changes similar to 
those observed in articular cartilage — including loss of cellularity, and disruption and 
degeneration of the extracellular matrix — suggesting that common processes could be 
involved.
In 2013, nine cellular and molecular hallmarks of ageing were proposed11 to highlight the 
underlying causes of age-related dysfunction and assist with research into potential 
therapeutic interventions. These hallmarks include genomic instability, telomere 
attrition, epigenetic alterations, loss of proteostasis, dysregulated nutrient sensing, 
mitochondrial dysfunction, cellular senescence, stem cell exhaustion and 
altered intercellular communication. This Review covers selected aspects of ageing that are 
relevant to OA and, where possible, relates these studies to the hallmarks of ageing.
 Ageing, inflammation and OA
Mounting evidence suggests that OA is associated with low-grade systemic and local 
inflammation12,13. Ageing has likewise been associated with chronic low-grade 
inflammation, sometimes referred to as ‘inflammaging’ (REF.14), which could promote OA, 
although studies to date have not identified the precise mechanisms. Several of the hallmarks 
of ageing could also have a role in OA, including epigenetic alterations, dysregulated 
nutrient sensing, mitochondrial dysfunction, cellular senescence and altered intercellular 
communication. As discussed further below, increased production of proinflammatory 
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mediators is a feature of the senescence-associated secretory phenotype (SASP) 
and could be an important mechanism in OA.
A key cytokine associated with ageing and age-related disease is IL-6. Levels of IL-6 in the 
systemic circulation increase with age15,16 and are strongly associated with the risk of OA 
progression17,18. IL-6 is important in the pathogenesis of rheumatoid arthritis, and IL-6 
inhibition is an effective therapy approved for clinical use in this setting19. However, a 
causal role for IL-6 in age-related OA has not been established, as mice with deletion of the 
Il6 gene have more severe (rather than less severe) age-related OA20, suggesting that other 
mediators could be involved. In addition, the levels of multiple proinflammatory and anti-
inflammatory mediators change with age16, and so it is unlikely that the association between 
age and OA is driven by a single factor.
Inflammaging is probably attributable, at least in part, to the age-related increase in visceral 
fat mass that is associated with a decline in muscle mass21. Obesity is a well-accepted risk 
factor for OA in all age-groups3. Reviews published elsewhere22,23 have detailed the 
potential mechanisms by which obesity leads to OA, and so here we will only summarize the 
key findings most relevant to age-related OA. The increase in fat mass with ageing is 
associated with increased numbers of adipocytes and proinflammatory macrophages in 
adipose tissue, and these cells produce a number of cytokines and adipokines that could 
contribute to OA24,25, although the importance of these mediators in OA remains unclear. 
Obesity and increased fat mass can also contribute to OA through metabolic alterations that 
are sometimes referred to as ‘meta-inflammation’ (REFS 22,23). In addition to increased 
levels of cytokines and adipokines, meta-inflammation is associated with increased levels of 
circulating free fatty acids, hyperglycaemia and oxidative stress, which can all negatively 
influence joint tissues to promote matrix destruction22,23. Furthermore, obesity associated 
with low muscle mass (that is, sarcopenic obesity) has been associated with knee OA26 and 
could contribute to joint instability and an increased risk of falls in older adults, particularly 
in women27.
In addition to an age-related increase in visceral fat, local fat depots such as the infrapatellar 
fat pad increase with age28. Given that this fat pad is proximal to the knee joint and produces 
the adipokines adiponectin and leptin, as well as basic fibroblast growth factor (bFGF; also 
known as FGF-2), vascular endothelial growth factor, TNF and IL-6 (REF. 29), it is 
plausible that an age-related increase in fat pad volume could contribute to OA. However, in 
vitro studies of conditioned media from infrapatellar fat pads removed from patients with 
end-stage knee OA found a protective rather than catabolic effect on bovine cartilage 
explants30.
 Cellular senescence and the SASP
Cellular senescence is one of the hallmarks of ageing, and chondrocytes have many features 
that are characteristic of senescent cells during ageing and during OA31,32. The observation 
that OA catalyses the development of senescence indicates that cellular stresses probably 
have a key role in establishing this phenotypic state. A key challenge has been deciding how 
to best define chondrocyte senescence and determine the underlying mechanisms that might 
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be targeted therapeutically (FIG. 1). Morphological changes and permanent replicative arrest 
after monolayer expansion have defined cellular senescence for in vitro settings, but defining 
cellular senescence in vivo has proved more difficult33.
Two distinguishing characteristics of senescent cells are stress-induced permanent 
proliferative arrest and resistance to both mitogenic and oncogenic stimuli33, both of which 
are challenging to assess in chondrocytes. Chondrocytes exhibit low proliferation rates, 
which hinders the measurement and interpretation of the functional impact of a further 
reduction in proliferation34. Lineage-tracing experiments in mice indicate that proliferation 
of particular chondrocyte subpopulations could help to maintain cartilage tissue35, 
suggesting, therefore, that the loss of proliferation in these cells due to senescence could 
contribute to OA progression. The other defining feature of senescence is a beneficial 
function of preventing the division of transformed cells36. Chondrosarcomas typically derive 
from the growth plate and perichondrium but not from articular cartilage37, suggesting that 
articular cartilage might be inherently unlikely to undergo uncontrolled growth. This 
characteristic presents a challenge for the identification of senescent chondrocytes on the 
basis of an increased resistance to oncogenic transformation.
Cellular senescence could have other functional roles aside from inhibition of proliferation, 
as the SASP is defined by the production of high levels of proinflammatory cytokines and 
matrix-degrading enzymes38. Indeed, the SASP seems to be regulated independently from 
cell cycle arrest39,40. Some of the most highly upregulated SASP-related factors, such as 
IL-1α, IL-6 and monocyte chemoattractant protein 1 (MCP-1, also known as CC chemokine 
ligand 2 (CCL2)) are found in OA cartilage41, hindering efforts to determine whether the 
level of a particular mediator is due to senescence or a result of OA. The cell type 
responsible for producing these cytokines is also difficult to determine. As these factors are 
also found in the synovial fluid, they could be produced by cells other than chondrocytes, 
such as cells in the meniscus, synovium or bone7. Future work is needed to determine 
whether any of these cell types display other features of senescence.
 The induction of chondrocyte senescence
A detailed understanding of how chondrocytes enter the senescent state might enable the 
development of therapies designed to prevent such a phenotypic switch during OA. One 
model proposes that senescence occurs during conditions characterized by simultaneous 
signals for cell cycle arrest and cell growth7,42, and aged cartilage tissue has the potential to 
provide both these cues.
The cumulative DNA damage and oxidative stress that occurs with ageing and in the OA 
tissue microenvironment alters gene expression patterns in chondrocytes7,43 and could cause 
telomere attrition due to targeted DNA damage41,44. Notably, stem cells and postmitotic 
cells such as neurons and chondrocytes can be particularly susceptible to the accumulation 
of cellular damage during the long interval between replicative events45,46. One common 
consequence of accumulating DNA damage is the upregulation of cell cycle inhibitors, such 
as cyclin-dependent kinase inhibitor 2A (also known as p16INK4A) and cyclin-dependent 
kinase inhibitor 1 (also known as p21), which mediate the stable arrest that is associated 
with senescence33. Evidence correlating increasing age and OA with increased CDKN2A 
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(p16INK4A) gene expression in chondrocytes has been complemented by mechanistic work 
showing that the suppression of p16INK4A expression by the microRNA miR-24 serves to 
prevent features of chondrocyte senescence47. These observations in chondrocytes seem to 
be aligned with a model explored in mouse muscle stem cells, in which increased p16INK4A 
expression with age made cells more likely to undergo senescence during subsequent 
proliferation after injury48.
The second signal required for establishing senescence, a strong growth signal, can be 
provided in the form of growth factors that are either directly released from damaged 
cartilage or synthesized at high levels by chondrocytes during OA. For example, bFGF is 
released from damaged cartilage tissue49, and can be detected in focal clusters of 
chondrocyte proliferation that develop near areas of cartilage damage50. As a downstream 
result of signalling by inflammatory cytokines associated with OA, expression of bone 
morphogenetic protein 2 (BMP-2) is increased,51 thereby stimulating enhanced turnover of 
extracellular matrix52. Although their competence for proliferation indicates that these 
chondrocytes are not senescent, cells that enter the cell cycle in the context of potentially 
damaging stimuli have an increased likelihood of entering senescence as opposed to 
returning to quiescence53,54. Observations that senescence occurs after monolayer expansion 
of chondrocytes (reviewed elsewhere55) provide further evidence that contexts of increased 
proliferation correlate with emergence of the senescent phenotype.
 The role of circadian signals
Also of potential interest is the finding that chondrocytes have an intrinsic circadian clock 
which is disrupted in cartilage from aged mice56. A decline in expression of the circadian 
clock gene BMAL1 (also known as ARNTL) has been associated with stress-induced 
senescence in fibroblasts57 and has been noted to occur in human OA chondrocytes and in 
the cartilage of aged mice58. Mice with cartilage-specific deletion of Bmal1 developed 
premature knee cartilage lesions that appeared at 2 months of age and became progressively 
more severe in adult animals58. However, no other OA-associated changes in the bone, 
ligaments or synovium were evident in these mice, and the finding that the cartilage changes 
were detectable before the mice were skeletally mature suggests that the phenotype is the 
result of a developmental defect rather than OA. Further work is needed to determine the 
role of BMAL1 and the circadian clock in age-related human OA.
 Therapeutic targeting of senescence
One emerging therapeutic strategy for age-related diseases is to specifically kill senescent 
cells in order to prevent detrimental secretion of SASP-related factors. Although this 
approach has not yet been explored in OA, the concept builds on studies that eliminated 
p16INK4A-positive cells in mouse models of premature59 and natural ageing60. Drugs that 
eliminate senescent cells in aged tissue would ideally mimic the efficient clearance of 
senescent cells that occurs after wound repair61. The ‘senolytic’ compounds dasatanib and 
quercetin target senescent cells by inhibiting the anti-apoptotic pathways that are 
upregulated in senescent cells62. One anti-ageing effect of this treatment was protection 
from proteoglycan loss in the intervertebral disc of Ercc1-mutant mice (a model of 
accelerated ageing based on compromised DNA damage repair). Although articular cartilage 
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was not investigated in this study, other work has shown that ERCC1-mediated DNA repair 
helped to restrain senescence in human articular chondrocytes63. A separate study further 
supports the strategy of inhibiting anti-apoptotic pathways by identifying navitoclax as an 
inhibitor of B-cell lymphoma family proteins that specifically targets senescent human 
fibroblasts in vitro and mouse stem cells in vivo64.
Another therapeutic approach could be to interfere with inflammatory pathways active in 
senescent chondrocytes. Rapamycin inhibits the translation of SASP proteins in human 
fibroblasts through decreasing the rate of IL-1α translation, which is regulated by serine/
threonine-protein kinase mTOR (also known as mammalian target of rapamycin)65. With 
increased progress in the understanding of how senescence is regulated in chondrocytes, 
particular cellular features could provide other novel drug targets for OA.
 Oxidative stress and the mitochondria
Mitochondrial dysfunction is a hallmark of ageing that has attracted particular attention in 
the context of OA. The free radical theory proposes that cellular damage occurring as a 
result of excessive levels of reactive oxygen species (ROS) substantially contributes to the 
development of the ageing phenotype and to the progression of age-related diseases66. 
However, in addition to cellular damage, elevated levels of ROS produced as a result of age-
associated oxidative stress also promote disease by disturbing homeostatic physiological cell 
signalling66–68.
Mitochondrial function has long been recognized to decline during ageing, and a causative 
link between mitochondrial dysfunction, oxidative stress and the ageing phenotype has been 
proposed66,69. Evidence from a 2015 study70 demonstrates that, compared with normal 
chondrocytes, chondrocytes from patients with OA have reduced mitochondrial mass and 
mitochondrial DNA content along with reduced levels of electron transport chain proteins 
and proteins involved in mitochondrial biogenesis. The researchers confirmed that some of 
these changes occurred during ageing and were independent of OA by analysing mouse 
cartilage tissue sections. Interestingly, protein levels of nuclear receptor erythroid 2-related 
factors 1 and 2 (also known as NFE2-related factor 1 and NFE2-related factor 2, 
respectively), which confer cellular protection through regulation of antioxidant gene 
expression, were also decreased in chondrocytes from patients with OA compared with those 
from healthy controls70.
As mitochondria are an important source of ROS, age-related mitochondrial dysfunction that 
leads to an imbalance between the production of ROS and the antioxidant capacity of the 
cell has been identified as a contributing factor in the development of OA68,71,72 (FIG. 2). 
Mice with post-traumatic OA showed elevated intracellular and mitochondrial superoxide 
generation, which was associated with downregulation of mitochondrial superoxide 
dismutase 2 (SOD2) expression73. Furthermore, in this same model, SOD2 loss resulted in 
greatly increased age-related cartilage degeneration73. In vitro studies using paraquat to 
induce mitochondrial superoxide generation in primary mouse articular chondrocytes led to 
substantial mitochondrial dysfunction, along with reduced expression of both antioxidant 
genes (including Sod2) and anabolic genes in cartilage, whereas catabolic gene expression 
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was upregulated73. These data are in accordance with other studies demonstrating 
downregulation of SOD2 expression at the mRNA and protein levels in cartilage from both 
humans74–76 and animals76 with OA, and support the hypothesis that mitochondrial 
dysfunction and the associated redox imbalance is a key mechanism contributing to cartilage 
degeneration and the pathogenesis of OA.
Consistent with the concept that age-related oxidative stress alters cell signalling, studies 
have demonstrated an age-related disruption in human chondrocyte insulin-like growth 
factor 1 (IGF-1) signalling that results in reduced extracellular matrix gene expression and 
protein synthesis77,78. In human chondrocytes from older adults, this effect was associated 
with an increased sensitivity to oxidative stress, which resulted in inhibition of IGF-1-
mediated activation of RACα serine/threonine-protein kinase (AKT) and increased 
activation of catabolic mitogen-activated protein kinase (MAPK) signalling pathways78.
A key mechanism by which ROS regulate cell signalling is through oxidative post-
translational modifications of specific thiol groups in proteins that contain reactive 
cysteines79. Cysteine oxidation initially results in the formation of a cysteine sulfenic acid 
(Cys-SOH) in a process known as S-sulfenylation. In a 2016 study, chondrocytes from 
patients with OA had an increased basal level of S-sulfenylation compared with those from 
healthy controls80. ROS induced sulfenylation of multiple chondrocyte proteins including 
the tyrosine kinase SRC, the activity of which promoted an increase in the production of 
matrix metalloproteinase 13 (MMP-13)80. These data suggest that ROS-induced 
sulfenylation of chondrocyte proteins can alter signalling pathways that can promote 
cartilage degradation.
In the presence of excessive levels of ROS, cysteine oxidation can proceed from cysteine 
sulfenic acid to sulfinic (Cys-SO2H) or sulfonic (Cys-SO3H) acid; this so-called 
hyperoxidation can lead to inactivation of redox-sensitive proteins. Hyperoxidation of the 
peroxiredoxin family of antioxidant enzymes has been demonstrated in cartilage samples 
from older adult humans and patients with OA81. Conditions of oxidative stress (induced in 
vitro with the ROS generator menadione) led to an age-related increase in peroxiredoxin 
hyperoxidation, which was associated with both inhibition of pro-survival cell signalling and 
p38 MAPK-induced chondrocyte cell death81. Importantly, reduction of ROS levels by 
mitochondrion-specific overexpression of the antioxidant enzyme catalase prevented 
peroxiredoxin hyperoxidation in vitro, and reduced the severity of age-related OA in mice in 
vivo81. Collectively, these studies highlight ROS as crucial secondary signalling molecules 
in chondrocytes that warrant further study in the context of ageing and OA.
 Dysfunctional energy metabolism
Another hallmark of ageing is dysregulated nutrient sensing. 5′-AMP activated protein 
kinase (AMPK) is a key regulator of cellular metabolism and energy balance that is activated 
by stressors that enhance the cellular AMP:ATP ratio82. The activity of AMPK and its 
regulatory upstream kinase, serine/threonine-protein kinase STK11 (also known as liver 
kinase B1 (LKB1)), is reduced in cartilage from aged mice and mice with OA, as well as in 
bovine chondrocytes after dynamic compression-induced biomechanical injury83. Similarly, 
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OA-associated reductions in AMPK activity have been observed in human chondrocytes and 
cartilage84, and this reduced activity has been associated with substantially reduced 
mitochondrial biogenesis70.
Importantly, AMPK might also modulate key homeostatic signalling pathways through 
regulation of autophagy, a cellular process that removes damaged and dysfunctional 
organelles and proteins82,85. Autophagy is relevant to another hallmark of ageing: loss of 
proteostasis. Transgenic overexpression of AMPK delays the onset of the ageing phenotype 
through direct upregulation of autophagy in Drosophila melanogaster, which ultimately 
increases the lifespan of these organisms86. Consistent with this observation, the expression 
of key autophagy proteins was considerably reduced in cartilage from aged mice compared 
with that from young mice, and these changes were associated with increased levels of 
apoptosis and cartilage degeneration87. Similar results were also found in a mouse model of 
post-traumatic OA88, implicating dysfunctional autophagy as a key mechanism in both 
ageing and OA. Although AMPK levels were not measured in these post-traumatic OA 
studies, other work has demonstrated that AMPK signalling stimulates autophagy in 
chondrocytes89. As inhibition of mTOR signalling is a widely investigated strategy to 
prevent age-related disease90, the fact that cartilage-specific loss of mTOR increased AMPK 
levels and autophagy, and was sufficient to protect mice from OA following surgery, is of 
particular interest91. Taken together, a plausible interpretation of these findings is that age-
related and OA-related reductions in AMPK signalling reduce autophagy and contribute to 
the cellular dysfunction observed in OA cartilage, a connection that is worthy of future 
investigation.
In addition to AMPK, many lines of evidence suggest that the evolutionarily conserved 
sirtuin (SIRT) family of NAD+-dependent deacetylase proteins also contributes to cellular 
homeostasis through regulation of energy balance. This regulation is achieved via direct 
nutrient sensing, which can contribute to increased lifespan in model organisms, such as 
worms and flies92. However, whether overexpression of sirtuins can have a direct longevity-
promoting effect remains unclear93. SIRT6 has been identified as a crucial regulator of 
processes that are hypothesized to be directly involved in ageing, including metabolic 
homeostasis, genome stability and transcription94. Sirt6-knockout mice display reduced 
IGF-1 levels and accelerated ageing-like degenerative processes that ultimately lead to 
premature death, which suggests a role for SIRT6 in ageing95. Similarly, male transgenic 
mice overexpressing Sirt6 had an increased lifespan, in part due to regulation of IGF-1 
signalling96, which suggests that age-related loss of SIRT6 activity could contribute to 
ageing by disturbing normal cell signalling pathways.
In cartilage, research has predominantly focused on the role of SIRT1 (reviewed 
elsewhere97). As such, there is a paucity of research on how other sirtuins regulate 
chondrocyte function. However, depletion of SIRT6 in human chondrocytes (achieved using 
RNA interference) resulted in substantially increased DNA damage and telomere 
dysfunction, which was associated with premature senescence98. SIRT6 depletion also 
increased expression of MMP1 and MMP13, which are implicated in the pathogenesis of 
OA. Compared with cells from normal human tissue, human OA chondrocytes show reduced 
expression of SIRT6 at both the mRNA and protein level, and lentivirus-induced 
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overexpression of SIRT6 in the knee joint protects young mice from surgically induced 
OA99. These studies highlight a potential role for SIRT6 in cartilage homeostasis that 
warrants further investigation.
 Changes in the extracellular matrix
Articular cartilage is a load-bearing tissue, and the ability of chondrocytes to sense and 
respond to mechanical signals is essential for maintaining joint homeostasis (reviewed 
elsewhere100). Accumulation of advanced glycation end-products (AGEs) with 
ageing causes non-enzymatic collagen crosslinking that directly alters the mechanical 
properties of the extracellular matrix101. However, a canine model using ribose and threose 
injections to increase AGE levels in young animals to match those of aged controls was 
insufficient to initiate OA102. Nevertheless, chondrocytes did synthesize fewer proteoglycans 
in the highly crosslinked tissue, which might indicate that compromised cellular function 
would prevent sufficient tissue maintenance in the context of ageing or injury. This 
possibility is supported by a study in rabbits, in which forced exercise in combination with 
ribose injections did induce OA, through AGE-mediated suppression of protective 
chondrocyte signalling103.
Whether limiting AGE accumulation would be sufficient to prevent age-related OA remains 
unclear, but genetic deletion of lysyl oxidase (an enzymatic collagen crosslinker that is 
upregulated by joint injury) protected mice from injury-induced OA104. The potential 
relevance of this finding to AGEs and thus ageing was suggested by the finding that collagen 
crosslinking induced by AGEs and by lysyl oxidase had similar effects on chondrocyte 
signalling in collagen gels and on the development of OA after injury.
Chondrocytes integrate signals from mechanotransduction pathways that sense changes in 
the extracellular matrix and those initiated by soluble factors, and both types of signals are 
affected by ageing. Mechanical compression of bovine cartilage stimulates increased 
expression of the gene encoding transforming growth factor-β (TGF-β) and the subsequent 
phosphorylation of SMAD2 and SMAD3 through TGFR-1 (TGF-β receptor type-1), which 
increases matrix synthesis and limits catabolic signalling105. However, ageing causes a 
significant loss in expression of TGFR-1, resulting in a shift that favours TGF-β signalling 
through serine/threonine-protein kinase receptor R3 (SKR3, also known as TGF-β 
superfamily receptor type I). SKR3-mediated signalling leads to phosphorylation of 
SMAD1, SMAD5 and SMAD8, which is associated with an increase in catabolic signalling 
and increased production of MMP-13 (REF. 106). In a 2016 study of bovine cartilage 
explants subjected to anabolic dynamic compression, tissues from aged animals had 
deficient phosphorylation of SMAD2 and SMAD3 in response to loading compared with 
explants from young animals105. The exact mechanism responsible for this effect is difficult 
to deduce because, compared with young explants subjected to the same load, aged tissue 
showed less deformation, exhibited less upregulation of growth factors and also had lower 
levels of TGFR-1 on the cell surface. However, previous work using a hydrogel system with 
varied stiffness revealed that mouse chondrocytes show a maximal response to exogenous 
TGF-β at a physiologically relevant stiffness of 500 kPa107, indicating that the age-related 
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increase in matrix stiffness probably contributes to the reduced phosphorylation of SMAD2 
and SMAD3 in aged tissue.
 Conclusions
Researchers are becoming increasingly interested in elucidating the mechanisms by which 
ageing promotes the development and progression of OA. Studies in the early 2000s detailed 
age-related changes in the extracellular matrix, such as the accumulation of AGEs, which 
could promote OA by altering the mechanical properties of joint tissues. Subsequent 
research has focused on age-related cellular changes that include not only an accumulation 
of damaged proteins, lipids and DNA, but also alterations in mitochondrial function, levels 
of ROS and energy metabolism that disrupt signalling and associated cell functions. These 
changes promote catabolic activity over anabolic activity and eventually result in cell death. 
We can easily envision how these changes could result in joint tissue degeneration and 
matrix loss, but the precise mechanisms need to be clarified. The concept of hallmarks of 
ageing suggests that common mechanisms will drive dysfunction in various tissues and 
organ systems that are most affected by ageing. These hallmarks represent areas for further 
research into elucidating the connections between ageing and OA. Although the majority of 
research into the effects of ageing continues to focus on articular chondrocytes, further 
studies are needed to determine whether similar mechanisms are at play in cartilage as well 
as other joint tissues affected by OA, in order to find common targets for intervention.
A primary goal of ageing research is to better understand common mechanisms that could be 
targeted with the intent of delaying loss of function in more than a single system, which 
would result in improved ‘healthspan’ rather than simply extending lifespan. Heterochronic 
parabiosis experiments, in which the circulatory systems of young and old animals are 
joined, have revealed systemic factors that alter the ageing phenotype, including growth and 
differentiation factor 11 (GDF11), oxytocin and IL-15, which might be able to reduce ageing 
in multiple organ systems108. An important aim of future studies will be to determine 
whether these ageing-associated factors influence the development of OA.
Another emerging approach is the development of senolytic agents that would target and 
remove senescent cells62,64. These and other therapies that target ageing processes could be 
developed into novel treatments for OA (BOX 3). Given the prevalence of conditions such as 
OA in older adults and the importance of the musculoskeletal system in physical function, 
achieving improvements in healthspan will certainly require interventions that benefit the 
musculoskeletal system.
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 Glossary
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Key points
• Ageing-associated changes promote the development of osteoarthritis (OA), 
but ageing and OA are independent processes
• Several hallmarks of ageing could contribute to OA: genomic instability, 
telomere attrition, epigenetic alterations, loss of proteostasis, dysregulated 
nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell 
exhaustion, and altered intercellular communication
• The increase in fat mass and related metabolic changes that occur with 
ageing can result in ageing-related inflammation (referred to as 
‘inflammaging’), a chronic low-grade systemic proinflammatory state
• Elevated levels of reactive oxygen species can contribute to OA by causing 
oxidative damage and disrupting normal cell signalling, leading to 
imbalanced anabolic and catabolic activity and ultimately cell death
• Chondrocytes can undergo cellular senescence with age and OA in response 
to growth signals released as a result of underlying cellular damage
• The non-enzymatic crosslinking of collagen that occurs with ageing alters 
the mechanical properties of cartilage, and the resulting changes to 
mechanotransduction pathways reduce extracellular matrix synthesis by 
chondrocytes
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Box 1
Age-related factors that contribute to osteoarthritis development
• Reduced muscle mass and increased fat mass alter joint loading and are 
associated with an increase in adipokine and cytokine production, resulting 
in low-grade systemic inflammation109.
• Changes in the extracellular matrix, including accumulation of advanced 
glycation end-products, reduced aggrecan size, reduced hydration, and 
increased collagen cleavage alter the mechanical properties of cartilage and 
make it more susceptible to degeneration31.
• Extracellular matrix disruption and reduced cell density in the meniscus and 
ligaments promote degeneration and can potentially alter joint 
mechanics8,9.
• Impairment in the function of subchondral bone due to reduced numbers of 
osteocytes and altered mineral composition10.
• Mitochondrial dysfunction, oxidative stress and reduced autophagy in 
chondrocytes alters their function, promoting catabolic processes and cell 
death over anabolic processes31.
Loeser et al. Page 18
Nat Rev Rheumatol. Author manuscript; available in PMC 2017 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Box 2
Differences between normal joint ageing and osteoarthritis
• With normal joint ageing, articular cartilage remains intact but loses 
thickness and has a reduced glycosaminoglycan (GAG) content. With 
osteoarthritis (OA), fibrillation of the cartilage surface occurs in focal areas 
and can be associated with a complete loss of staining for GAGs31,110.
• Non-enzymatic crosslinking of collagen by advanced glycation end-
products (AGEs) increases in cartilage with age. A mouse model of injury-
induced OA demonstrated that collagen crosslinking occurs through a 
distinct mechanism involving lysyl oxidase104.
• The density of chondrocytes in cartilage decreases with age, but 
chondrocyte ‘clusters’ emerge during the development of OA near sites of 
tissue damage and may indicate attempted repair or altered cellular 
signals31,110.
• Aged chondrocytes have reduced levels of extracellular matrix gene 
expression and synthesis, whereas during OA chondrocytes become highly 
active with increases in both anabolic processes (for example, matrix 
synthesis) and catabolic pathways (for example, those induced by 
inflammatory cytokines)31,110.
• Synovial inflammation and hypertrophy occur in OA but have not been 
described in normal joint ageing7.
• Bone mass and density decrease with ageing, whereas subchondral bone 
thickening is seen in patients with OA7.
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Box 3
Therapeutic targeting of ageing-related processes in osteoarthritis
• Interventions designed to extend ‘healthspan’ by targeting systemic ageing-
related processes could potentially delay or prevent various chronic 
diseases, including osteoarthritis111,112.
• Senolytics, such as dasatanib and quercetin, are being designed to 
specifically kill senescent cells; removal of these cells might alleviate their 
harmful effects on neighbouring cells, including the release of 
proinflammatory factors that characterize the senescence-associated 
secretory phenotype (SASP)62.
• Agents that activate 5′-AMP-activated protein kinase (AMPK), such as 
metformin, could restore physiological levels of autophagy and promote 
proteostasis112.
• Sirtuin activators could restore normal nutrient sensing and energy 
metabolism112.
• Antioxidants targeted to the mitochondria or designed to restore 
homeostatic redox signalling could counteract mitochondrial dysfunction 
and altered intracellular signalling113.
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Figure 1. Chondrocytes exhibit features of cellular senescence in the contexts of ageing and 
osteoarthritis
Senescence is often caused by the combination of growth and arrest signals, conditions that 
can occur in cartilage during ageing. Features of senescence include expression of CDKN2A 
(encoding p16INK4A) and positive staining for senescence-associated β-galactosidase. The 
functional effects of chondrocyte senescence are challenging to measure because of the low 
proliferation rate of chondrocytes and the overlap between features of the senescence-
associated secretory phenotype (SASP) and those associated with the development of 
osteoarthritis (OA). Understanding the mechanism of senescence could yield therapeutic 
interventions to prevent development of the SASP or specifically eliminate senescent cells 
from joint tissues. MMPs, matrix metalloproteinases.
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Figure 2. Mitochondrial dysfunction, oxidative stress and changes in normal cell signalling in 
ageing and osteoarthritis
Mitochondrial dysfunction in both ageing and osteoarthritis (OA) is characterized by 
reduced mitochondrial integrity (mass, number and DNA content) and impaired electron 
transport chain (ETC) function. These features contribute to increased production of reactive 
oxygen species (ROS). Concomitant reductions in mitochondrial antioxidant capacity — 
including reduced mitochondrial superoxide dismutase 2 (SOD2) levels and peroxiredoxin 
(PRX) hyperoxidation — lead to enhanced oxidative stress and ROS-mediated damage in 
the mitochondria (indicated by red lightning bolts). Extra-mitochondrial antioxidant systems 
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(namely, SOD1, catalase and glutathione synthetase; not shown) are also considerably less 
active in ageing and OA, which exacerbates oxidative stress. ROS cause damage to proteins, 
lipids and DNA, increase chondrocyte catabolism and, importantly, lead to disturbances in 
normal cell signalling. These disturbances can include inhibition of pro-survival IGF-1 
signalling and increased catabolic mitogen-activated protein kinase (MAPK) signalling. 
Increased levels of ROS can also result in increased protein thiol oxidation, resulting in S-
sulfenylation or, when excessive, hyperoxidation of reactive protein cysteines, which might 
contribute to altered cell signalling. mtDNA; mitochondrial DNA; ERK, extracellular signal-
regulated kinase; IGFR, insulin-like growth factor receptor; IRS-1, insulin receptor substrate 
1.
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